Extra checks for complex scripts

Six specialists, called in as the script needs them.

Qiri does not screen a script with one general model. Six specialist checks reason over it in their own domain, and a pharmacist signs the result. Most scripts need only the pharma specialist. The other five are called in when a script needs them.

Pharma specialist

Most scripts are screened by this specialist alone. It works the whole medication profile: interaction chains, renal and hepatic dose review, allergy and contraindication checks, LASA risk, and therapeutic duplication.

  • Interaction chains

    The whole medication list at once, not one drug pair at a time.

  • Dose verification

    Dose read against the patient's renal and hepatic function, surfaced for the pharmacist to review.

  • Allergy and contraindication

    The patient's allergy record against every active script, before supply.

  • LASA detection

    Look-alike, sound-alike pairs caught at entry, not at the shelf.

  • Therapeutic duplication

    Two medicines doing one job, flagged before the patient takes both.

Clinical pharmacology specialist

Some scripts turn on the patient's metabolism rather than the drug list. Those come here: cytochrome P450 pathways, PK/PD behaviour, pharmacogenomic results, and therapeutic drug monitoring.

  • CYP450 metabolism

    Inhibitors, inducers and substrates across the P450 enzyme families.

  • Pharmacogenomics

    Genetic results read as poor, intermediate or ultra-rapid metaboliser phenotypes, with high-risk drug-gene pairs flagged against published pharmacogenomic guidelines.

  • Therapeutic drug monitoring

    Serum levels, sample timing, and the dose change that follows.

Oncology specialist

Chemotherapy leaves the least room for error of anything a pharmacy dispenses. This specialist verifies the regimen against protocol, tracks cumulative dose against toxicity ceilings, and flags where a patient sits outside the trial population the guideline was built on.

  • Protocol verification

    Regimens against recognised oncology protocol libraries: cycle timing, drug combinations, pre-medications.

  • Tumour-specific dosing

    Tumour type, stage, body surface area, and organ function.

  • Cumulative toxicity

    Lifetime dose against known ceilings, such as anthracycline cardiotoxicity and platinum nephrotoxicity.

  • Supportive care

    Anti-emetic, growth factor and prophylactic cover matched to the cycle.

Regulatory specialist

Pharmacy answers to a medicines regulator, a subsidy scheme, and controlled-substance schedules that vary by jurisdiction. This specialist puts them in front of the pharmacist before a supply happens, and the pharmacist makes the call.

  • Scheduling & registration

    Scheduling and registration status, read at the moment of supply.

  • Unapproved medicines

    The approval pathways and prescriber notifications your jurisdiction requires for unapproved and special-access medicines.

  • Subsidy authority

    Eligibility criteria, restriction codes, and authority conditions for subsidised supply.

  • Poisons schedules

    Controlled-substance schedules, and support for the record-keeping the most tightly controlled classes require.

Patient advocacy specialist

A correct dispense the patient does not understand is not a finished job. This specialist sets counseling to the patient's literacy and language, and points to the support services they are entitled to.

  • Health literacy

    Instructions and side-effect warnings pitched at the patient's reading level.

  • Language

    Counseling and patient materials in the patient's own language.

  • Adherence

    Patients drifting off their medicine, early enough to do something about it.

  • Support services

    Subsidy safety-net thresholds, and the public health, mental-health, aged-care and disability support pathways patients are entitled to.

  • Cultural safety

    Cultural safety for First Nations and culturally and linguistically diverse communities.

Qiri

Extra checks in action

No extra screen, and no separate compliance step at the end of the month.